|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
SI2511297T1
(sl)
|
2004-02-06 |
2015-07-31 |
Morphosys Ag |
Proti -CD38 humana protitelesa in njihova uporaba
|
|
KR20140066259A
(ko)
*
|
2004-02-06 |
2014-05-30 |
모르포시스 아게 |
항-ｃｄ３８ 인간 항체 및 그의 용도
|
|
MX2007011064A
(es)
|
2005-03-23 |
2008-02-19 |
Genmab As |
Anticuerpos contra cd38 para tratamiento de mieloma multiple.
|
|
RU2425841C2
(ru)
|
2005-10-12 |
2011-08-10 |
МорфоСис АГ |
Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
|
|
LT2548577T
(lt)
*
|
2005-12-29 |
2017-04-10 |
Janssen Biotech, Inc. |
Žmogaus anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
|
|
JP5328018B2
(ja)
*
|
2006-06-05 |
2013-10-30 |
国立大学法人広島大学 |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
AU2013209322A1
(en)
*
|
2006-10-19 |
2013-08-15 |
Sanofi-Aventis |
Novel anti-cd38 antibodies for the treatment of cancer
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
|
WO2012041800A1
(en)
|
2010-09-27 |
2012-04-05 |
Morphosys Ag |
Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
|
|
US9114131B2
(en)
*
|
2010-10-05 |
2015-08-25 |
Daiichi Sankyo Company, Limited |
Antibody targeting osteoclast-related protein Siglec-15
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
PT2900232T
(pt)
|
2012-09-25 |
2018-02-09 |
Morphosys Ag |
Combinações e suas utilizações
|
|
WO2014068114A1
(en)
|
2012-11-05 |
2014-05-08 |
Morphosys Ag |
Radiolabelled antibody and uses thereof
|
|
JP2014117191A
(ja)
*
|
2012-12-13 |
2014-06-30 |
Fisheries Research Agency |
リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
|
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
NZ713641A
(en)
*
|
2013-04-29 |
2019-08-30 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
US9493563B2
(en)
|
2013-11-04 |
2016-11-15 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
KR20230022270A
(ko)
*
|
2014-03-28 |
2023-02-14 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
EP3154581B1
(en)
|
2014-06-16 |
2019-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
ES2870449T3
(es)
|
2014-10-29 |
2021-10-27 |
Bicyclerd Ltd |
Ligandos peptídicos bicíclicos específicos de MT1-MMP
|
|
IL251822B2
(en)
|
2014-10-29 |
2023-03-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Variants of interferon alpha-2-b
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
WO2016164669A2
(en)
*
|
2015-04-08 |
2016-10-13 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
|
WO2016180958A1
(en)
|
2015-05-13 |
2016-11-17 |
Morphosys Ag |
Treatment for multiple myeloma (mm)
|
|
HK1253242A1
(zh)
|
2015-05-20 |
2019-06-14 |
Janssen Biotech, Inc. |
用於治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
|
|
EP3636660A1
(en)
|
2015-05-30 |
2020-04-15 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
US10668149B2
(en)
|
2015-06-22 |
2020-06-02 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
CA2990620A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
AU2016350717B2
(en)
|
2015-11-03 |
2023-08-10 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
IL305540B2
(en)
|
2016-03-04 |
2024-09-01 |
Morphosys Ag |
Clinical evaluation of protein-M response in multiple myeloma
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
EP4050032A1
(en)
|
2016-06-28 |
2022-08-31 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
US10478497B2
(en)
|
2016-07-20 |
2019-11-19 |
Hybrigenics S.A. |
Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
|
|
CN110997722B
(zh)
|
2017-06-08 |
2023-09-26 |
黑带医疗有限公司 |
Cd38调节抗体
|
|
US11780930B2
(en)
*
|
2017-06-08 |
2023-10-10 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
CN110997009B
(zh)
|
2017-06-20 |
2025-01-21 |
索伦托药业有限公司 |
Cd38抗体药物缀合物
|
|
US10899798B2
(en)
|
2017-06-26 |
2021-01-26 |
Bicyclerd Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
WO2019025811A1
(en)
|
2017-08-04 |
2019-02-07 |
Bicycletx Limited |
SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
|
|
AU2018316522B2
(en)
|
2017-08-16 |
2025-02-20 |
Black Belt Therapeutics Limited |
CD38 antibody
|
|
US11542338B2
(en)
|
2017-08-16 |
2023-01-03 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
SG11202000321PA
(en)
|
2017-08-16 |
2020-02-27 |
Black Belt Therapeutics Ltd |
Cd38 modulating antibody
|
|
AU2018348093A1
(en)
*
|
2017-10-10 |
2020-05-28 |
Sanofi |
Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
|
|
KR20200079293A
(ko)
|
2017-10-31 |
2020-07-02 |
얀센 바이오테크 인코포레이티드 |
고위험 다발성 골수종을 치료하는 방법
|
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
EP3694546A1
(en)
|
2018-01-30 |
2020-08-19 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN110144008B
(zh)
|
2018-02-12 |
2021-03-19 |
杭州尚健生物技术有限公司 |
Cd38蛋白抗体及其应用
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810320D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to CD38
|
|
AU2019362868A1
(en)
|
2018-10-17 |
2021-05-13 |
Janssen Biotech, Inc. |
Method of providing subcutaneous administration of anti-CD38 antibodies
|
|
IL283192B2
(en)
|
2018-11-20 |
2025-10-01 |
Janssen Biotech Inc |
A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3893841A1
(en)
|
2018-12-14 |
2021-10-20 |
MorphoSys AG |
Antibody formulations
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
GB201900530D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for CD38
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
TW202102541A
(zh)
|
2019-03-15 |
2021-01-16 |
德商莫菲西斯公司 |
用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
|
|
AU2020279987A1
(en)
|
2019-05-23 |
2021-11-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
MX2022000016A
(es)
|
2019-06-27 |
2022-02-24 |
Crispr Therapeutics Ag |
Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
|
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CN115362171A
(zh)
*
|
2020-03-31 |
2022-11-18 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
US20220023344A1
(en)
|
2020-06-26 |
2022-01-27 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19
|
|
CN114075283A
(zh)
*
|
2020-08-12 |
2022-02-22 |
三生国健药业（上海）股份有限公司 |
结合人cd38的抗体、其制备方法和用途
|
|
CN114195893A
(zh)
*
|
2020-09-17 |
2022-03-18 |
百奥泰生物制药股份有限公司 |
抗整联蛋白抗体或抗原结合片段及其应用
|
|
GB202016331D0
(en)
|
2020-10-15 |
2020-12-02 |
Bicyclerd Ltd |
Bicyclic peptide ligand drug conjugates
|
|
US20220202859A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
|
AU2022208200A1
(en)
|
2021-01-14 |
2023-07-20 |
Morphosys Ag |
Anti-cd38 antibodies and their uses
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
US20220378829A1
(en)
|
2021-05-12 |
2022-12-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating solid tumors
|
|
AR125851A1
(es)
|
2021-05-12 |
2023-08-16 |
Crispr Therapeutics Ag |
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|
|
KR20240099411A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
|
|
WO2023098813A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Nanjing Leads Biolabs Co., Ltd. |
Antibodies binding cd38 and uses thereof
|
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|